Skip to main content

Table 3 Sensitivity and specificity data for faecal calprotectin in adenomas and advanced adenomas

From: The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis

Author Year n Cut-off Standard-ised cut-off Sens (%) Spec (%) PPV (%) NPV (%) Comment
Total Adenoma (%) AA (%)
Adenomas            
Kronborg 2000 814 203 (24.9) 10 mg/l 50 43.0  
Tibble 2001 233 29 (12.4) 10 mg/l 50 55.0 85.2* 45.7* 89.3*  
Kristinsson 2001 237 73 (30.8) 17 (7.2) 10 mg/l 50 56.2 47.4 40.6* 62.8*  
      15 mg/l 75 45.2 59.6 41.8* 63.0*  
      20 mg/l 100 31.5 71.1 41.1* 61.8*  
Damms 2008 140 29 (20.7) 50 μg/g 50 55.0 79.0 57.0 77.0  
Kalimutho 2011 192 69 (35.9) 34 (17.7) 45.8 ng/ml   28.0 25.0* 21.0* 34.0*  
Widlak 2016 430 42 (9.8) 50 μg/g 50 43.0 56.0 10.0* 90.0*  
Rutka 2016 95 36 (37.9) 20 (21.1)    Faecal calprotectin significantly lower in low-risk adenoma compared to CRC
Advanced adenomas            
Hoff 2004 2321 195 (8.4) 50 μg/g 50 26.7* 76.1* 12.5* 89.0*  
Mowat 2015 755 41 (5.4) 50 μg/g 50 58.5 37.8 5.3 93.8  
      200 μg/g 200 19.5 73.7 4.3 93.8  
Lue 2020 404 41 (10.1) 39 (10) 50 μg/g 50 66.6 48.8 12.2 93.2  
Parente 2012 280 85 (30.4)    Significant differences between faecal calprotectin in both CRC and AA, and normal and AA (p < 0.001)
Turvill 2016 654 33 (5.0)    30/33 (90.9%) patients with AA had a high faecal calprotectin
  1. *Calculated value, AA advanced adenoma, PPV positive predictive value, NPV negative predictive value, standardised Cut-off: μg/g or mg/l multiplied by 5, –: no information available/ unable to calculate based on available information